论文部分内容阅读
文章讨论了细胞修复治疗在缺血性心脏病中的应用。介绍了不同类型细胞的心脏修复效应。重点介绍了胚胎干细胞(ESCs)及诱导型多能干细胞(iPS)临床应用障碍,而ESC及iPS源心脏前体细胞,心肌源性干细胞等修复心肌的最新进展。尤其重点描述了来自于人胚外或胚胎中胚层的脐带华通胶源间充质干细胞的细胞生物学特性,如:兼有胚胎干细胞及间充质干细胞标志特征,无伦理道德问题,多向分化而无致肿瘤性,多代增殖保持干性特征,独特的免疫调节功能等,使之WJ-MSCs将成为心脏再生医学中最具希望的种子细胞。
The article discusses the use of cell repair in ischemic heart disease. Cardiac repair effects of different types of cells are introduced. The clinical application of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS) is highlighted. Recent advances in the repair of cardiac myocytes, such as ESC and iPS-derived cardiac precursors and cardiomyogenic stem cells, are highlighted. In particular, the cell biological characteristics of umbilical cord blood derived from mesenchymal stem cells derived from extraembryonic embryos or embryonic mesoderm, such as the characteristics of embryonic stem cells and mesenchymal stem cells, ethical and ethical issues, multidirectional Differentiation without tumorigenicity, multi-generational proliferation to maintain dry features, unique immunomodulatory function, so that WJ-MSCs will be the most promising seed cells in cardiac regenerative medicine.